FastMarket.news

Synopsys Stops China Sales in Response to U.S. Export Restrictions

Published 1 days agoSNPS
Synopsys Stops China Sales in Response to U.S. Export Restrictions

Synopsys, a major player in the semiconductor design software sector, has put a halt on all sales and services to China following new U.S. export restrictions. As of May 29, 2025, Synopsys instructed its Chinese branches to cease any sales and stop processing new orders, complying with the directive from the U.S. Bureau of Industry and Security, which stipulates that shipments to China require a license.


This development significantly affects the electronic design automation market, where Synopsys, along with competitors Cadence and Siemens EDA, holds considerable influence. Chinese semiconductor companies rely heavily on the tools provided by these U.S. firms to develop chips. According to Reuters, Synopsys has a notable market share in China, making this suspension impactful on the local industry's access to critical technology.


In light of these restrictions, Synopsys has also paused its financial predictions for both annual and quarterly performance, citing unpredictability brought about by the recent changes. Additionally, the company has ensured compliance with the export controls by disabling Chinese clients’ access to its SolvNetPlus support platform. This move reflects broader efforts by the U.S. to limit China's reach into essential semiconductor technologies, further intensifying trade tensions between the two nations.

Share this article

Recent Articles

Jefferies Upgrades Unity Software Inc. to 'Buy' Amid Revenue Growth Optimism

Jefferies Upgrades Unity Software Inc. to 'Buy' Amid Revenue Growth Optimism

11 minutes agoU

Jefferies has upgraded Unity Software Inc. (NYSE: U) to a 'Buy' rating, emphasizing the expectation of accelerating revenue growth. This change on October 19, 2023, came with an increased price target of $28, up from the previous 'Underperform' rating. Nasdaq reported this move, highlighting the analyst's optimistic outlook on Unity's performance. The upgrade stems from anticipated growth in Unity's 'Create' segment, expected to boost revenues in the first half of the year. Benzinga reported on the company's strategic developments, notably the launch of 'Vector,' a self-learning AI platform designed to enhance ad performance, further supporting confidence in Unity's future financial results. Despite a 25% year-over-year revenue drop in the fourth quarter of 2024, Unity managed to exceed analyst expectations with $457 million. Benzinga also noted Unity's strong market presence, with its technology used in a major portion of top mobile games. With these strategic advancements, Unity aims to solidify its position and capitalize on growth opportunities.

Gilead Sciences' Trodelvy and Keytruda Combo Shows Promise in Breast Cancer Treatment

Gilead Sciences' Trodelvy and Keytruda Combo Shows Promise in Breast Cancer Treatment

26 minutes agoGILD

Gilead Sciences' Trodelvy, when paired with Merck's Keytruda, has exhibited notable success in combating advanced triple-negative breast cancer (TNBC). Results from the Phase 3 ASCENT-04/KEYNOTE-D19 trial revealed a significant improvement in treatment outcomes. This combination therapy demonstrated a median progression-free survival of 11.2 months, markedly better than the 7.8 months for patients receiving standard chemotherapy alongside Keytruda, according to Reuters. The trial also highlighted an improved median response duration for the Trodelvy-Keytruda treatment, clocking in at 16.5 months, compared to just 9.2 months in the chemotherapy group. Reuters reported that the safety profile of the combination therapy remained consistent with the known effects of each drug individually, and no new safety issues emerged. These findings suggest the Trodelvy-Keytruda regimen could soon become a preferred option for treating advanced TNBC, offering a potential new standard of care for this particularly aggressive cancer subtype. However, ongoing evaluation and broader adoption are necessary to confirm its effectiveness on a wider scale.

DoorDash Boosts Global Presence with Major Acquisitions

DoorDash Boosts Global Presence with Major Acquisitions

41 minutes agoDASH

DoorDash, led by CEO Tony Xu, has taken a significant step to expand its global reach with the announced acquisitions of UK-based Deliveroo and hospitality software firm SevenRooms. In May 2025, DoorDash agreed to purchase Deliveroo for £2.9 billion, equivalent to $3.9 billion, in a deal that offers a 29% premium over Deliveroo's previous share price. As reported by AP News, this acquisition bolsters DoorDash's presence in Europe, Asia, and the Middle East. In addition to the Deliveroo deal, DoorDash is set to acquire SevenRooms for $1.2 billion. This acquisition aims to enhance DoorDash's restaurant services and solidify its standing in the food delivery market. By integrating SevenRooms' software capabilities, DoorDash seeks to offer more comprehensive solutions to restaurants and improve its service offerings. These strategic moves mark DoorDash's most significant acquisitions since its purchase of Wolt Enterprises in 2022, according to Reuters. The company's aggressive expansion into new markets aims to fortify its position against competitors such as Just Eat and Uber Eats. By broadening its international footprint, DoorDash continues to consolidate the food delivery industry under Tony Xu's leadership.

Moderna's New COVID-19 Vaccine Wins FDA Approval

Moderna's New COVID-19 Vaccine Wins FDA Approval

1 hours agoMRNA

Moderna has received FDA approval for its latest COVID-19 vaccine, mNEXSPIKE, specifically for adults aged 65 and older, as well as individuals 12 to 64 with at least one underlying health condition. This development marks a significant step for Moderna, as it aims to address the changing landscape of vaccine demand. Reuters reported that this approval follows the FDA's updated guidelines, which now require testing against inert placebos for healthier, younger adults. The mNEXSPIKE vaccine presents several logistical advantages, notably its capability to be stored in a refrigerator, which improves shelf life and simplifies distribution. Clinical trials have shown that the vaccine not only matches but exceeds the efficacy of Moderna's original Spikevax vaccine. Moderna plans to make mNEXSPIKE available during the 2025-2026 respiratory virus season, coinciding with a time when demand for their earlier vaccines has waned. Amid this approval, the vaccine environment remains dynamic. The CDC, under Robert F. Kennedy Jr., continues to assert that COVID-19 vaccines are optional for children, underscoring the varied regulatory approaches to vaccination. Meanwhile, Moderna has also decided to pull its application for a combination flu-COVID vaccine, opting to await more data to support its efficacy.